X4 Pharma chairman Craig R. sells $210,829 in shares

X4 Pharmaceuticals Chairman Craig R. sold a substantial amount of company shares on August 12, 2026, totaling 47,436 shares valued at $210,829. The shares were sold at a weighted average price of $4.4445, with individual sales ranging from $4.33 to $4.55 per share. This transaction was primarily aimed at fulfilling personal income tax obligations resulting from the settlement of a restricted stock unit award.

The company's stock has demonstrated robust performance recently, with a 26% increase over the past six months and a 46% surge over the past year. Analysts remain optimistic about X4 Pharmaceuticals, setting price targets ranging from $10 to $13, indicating significant upside potential from the current share price of approximately $4.29. Following this share sale, Mr. R. now beneficially owns 328,651 shares of X4 Pharmaceuticals common stock, with 193,254 shares representing restricted stock units.

For a more detailed examination of X4 Pharmaceuticals' financial standing and growth potential, InvestingPro provides comprehensive analysis, including Fair Value estimates and exclusive ProTips. Recently, the company has attracted attention from analysts, with positive ratings. Wells Fargo initiated coverage on X4 Pharmaceuticals with an overweight rating, targeting a price of $11.00, based on the potential of their drug candidate, mavorixafor, in treating chronic neutropenia.

This Phase 3 trial is expected to yield results in the second half of 2027, with Wells Fargo assigning an approximately 80% probability of success, supported by positive Phase 2 data. Additionally, Leerink initiated coverage on X4 Pharmaceuticals with an outperform rating and a price target of $12.00, expressing confidence in mavorixafor's commercial potential, especially considering its approval in the U.S. and Europe for the rare disease WHIM syndrome.

These analyst ratings underscore the optimism surrounding X4 Pharmaceuticals' lead program and its future outlook.